$6.05
+0.03(0.41%)
Mkt Cap $394M
$1.00
$7.04
52-Week Range
At a Glance
AI-generatedZura Bio Limited (ZURA), a clinical-stage biotech, reported a net loss of $68.7 million for FY 2025, up 31% YoY from $52.4 million in 2024, driven by higher operating expenses of $75.2 million, a 36% increase primarily from research and development costs rising 72% to $42.1 million due to Phase 2 trials for tibulizumab (ZB-106) in hidradenitis suppurativa (TibuSHIELD, topline Q4 2026) and diffuse cutaneous systemic sclerosis (TibuSURE, topline H1 2027).
8-K
Zura Bio Limited reported full year 2025 financial results with net loss of $68.7 million, R&D expenses of $42.1 million, and cash and cash equivalents of $109.4 million as of December 31, 2025, alongside updates on ongoing Phase 2 tibulizumab trials and a February 2026 public offering raising $144 million gross proceeds, extending cash runway through at least end of 2028.$394M
Market Cap
—
Revenue
-$69M
Net Income
Employees30
Fundamentals
How The Business Makes Money
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001855644
ISINKYG9TY5A1016
Phone858 247 0520
Address4225 Executive Square, San Diego, CA, 92037, US
SEC EDGAR